Isorad radiopharmaceutical Division is the leader of the nuclear medicine industry in Israel for over 40 years. We are the first Israeli manufacturer serving nuclear medicine centers in Israel. Our mission is to provide pioneering medical imaging solutions, in order to improve the treatment of human disease, and to be a global supplier of products for nuclear medicine.
Isorad produces radiopharmaceuticals for SPECT (Single Photon Emission Computed Tomography). One of these is Tc-99m sodium pertechnetate solution produced by the Mo99 / Tc99 Generator, which is used for brain, thyroid and joint scintigraphies, angioscintigraphy, and angio-cardioscintigraphy and which attaches itself to MDP, DTPA, DMSA and MIBI to facilitate the analysis of a variety of illnesses. Others are the Thallium-201 injection solution used for myocardium, muscle perfusion, parathyroid scintigraphies, and tumor imaging, and Iodine-131 oral capsules and oral solution used in the diagnosis and treatment of thyroid disorders.
In 2001, Isorad radiopharmaceutical Division has began producing F18 FDG (Florodeoxy-D-glucose) at its plant in the Soreq, this way enabling nuclear medicine centers in Israel to start using PET (Positron emission tomography) imaging. In 2011, Isorad radiopharmaceutical Division has begun to supply LU177 for treatment.
In addition to sales in Israel, Isorad serves markets in India, Brazil, Colombia, Belarus, and Philippine as well as various other countries in the Middle and Far East. With the completion of its registration process in the European Union, Isorad aims to market its Radiopharmaceutical products in EU countries. For more than half a century, Isorad Ltd. has helped physicians enhance patient care with its pioneer ing product portfolio, that illuminates the heart and other organs. The company grew to become a leader in the field of diagnostic imaging.